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Immunophenotypic characterization of B-cell chronic lympho-
proliferative disorders (B-CLPD) is becoming increasingly complex
due to usage of progressively larger panels of reagents and a high
number of World Health Organization (WHO) entities. Typically,
data analysis is performed separately for each stained aliquot
of a sample; subsequently, an expert interprets the overall
immunophenotypic proﬁle (IP) of neoplastic B-cells and assigns
it to speciﬁc diagnostic categories. We constructed a principal
component analysis (PCA)-based tool to guide immunophenotypic
classiﬁcation of B-CLPD. Three reference groups of immuno-
phenotypic data ﬁlesFB-cell chronic lymphocytic leukemias
(B-CLL; n¼10), mantle cell (MCL; n¼10) and follicular lympho-
mas (FL; n¼10)Fwere built. Subsequently, each of the 175
cases studied was evaluated and assigned to either one of
the three reference groups or to none of them (other B-CLPD).
Most cases (89%) were correctly assigned to their corre-
sponding WHO diagnostic group with overall positive and
negative predictive values of 89 and 96%, respectively. The
efﬁciency of the PCA-based approach was particularly high
among typical B-CLL, MCL and FL vs other B-CLPD cases.
In summary, PCA-guided immunophenotypic classiﬁcation of
B-CLPD is a promising tool for standardized interpretation
of tumor IP, their classiﬁcation into well-deﬁned entities and
comprehensive evaluation of antibody panels.
Leukemia (2010) 24, 1927–1933; doi:10.1038/leu.2010.160;
published online 16 September 2010
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Introduction
Currently, ﬂow cytometers used in most clinical diagnostic
laboratories are not equipped with enough multicolor capabil-
ities to address many frequent clinical questions directed to
immunophenotyping with only one combination of monoclonal
antibodies.
1–7 In order to overcome such limitation, several
aliquots of the same sample are stained in parallel with a panel
of different, but partially overlapping monoclonal antibody
(MAb) combinations.
1,2,8–13 Recently, we have proposed a
mathematical approach which allows direct calculation of the
immunophenotypic features of individual cellular events for an
unlimited number of ﬂow cytometric parameters; the end result
is a single data ﬁle where individual cells are characterized for
all markers tested in a sample, for every individual aliquot
measured.
14 This new approach has proven to be of great utility
for the automated distinction between normal and neoplastic
cells coexisting in peripheral blood (PB), even when the latter
are present at very low frequencies.
15 However, no study has
been reported so far, in which a similar strategy is applied to
compare the immunophenotypic patterns of neoplastic cells
from individual patients with hematological malignancies,
for example, B-cell chronic lymphoproliferative disorders
(B-CLPD), with X1 set of reference cases of well established
World Health Organization (WHO) entities; such a tool could
be of great help for the interpretation of IPs, particularly
in complex or atypical cases.
In this study, we describe an automated pattern-guided
principal component analysis (PCA)
14 approach for the classi-
ﬁcation of ﬂow cytometry data. For its evaluation, a group of
small B-cell chronic leukemias and lymphomas was selected as
a model to compare the performance of the new approach here
proposed vs the WHO classiﬁcation. Small B-cell CLPD are
particularly suited for this type of evaluation because complex,
highly heterogeneous and partially overlapping immunopheno-
typic features are observed within these patients, for the different
WHO diagnostic groups.
1,2,9,16–19 Evaluation of the overall IPs
of neoplastic B-cells typically requires multiple markers (nX20)
in 3- to 10-color stainings
1,2,9,16–19 and interpretation by highly
experienced professionals. Finally, despite clear consensus
recommendations and guidelines have been proposed,
7,20–22
variable staining proﬁles are obtained when different MAb
clones, ﬂuorochrome conjugates and commercial sources
are used. Because of this and other factors, disturbing levels
of variability are generated among different centers as well
as among different professionals within the same laboratory, as
regards ﬁnal interpretation of the IPs of neoplastic B-cells in
small B-cell CLPD; this is particularly true for cases which
display immunophenotypic features that only show partial
overlap with well deﬁned entities, for example: atypical chronic
lymphocytic leukemia (CLL).
23
Here, we built a new PCA-based procedure for both assign-
ment of individual cases to speciﬁc WHO diagnostic subgroups
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entiating among them. The panel used for the construction of
this new approach was chosen among those 3- and 4-color
panels, currently in-use, before the design of 8-color EuroFlow
panels. Overall, our results suggest that this new procedure can
be of great help for the standardization of immunophenotypic
interpretation of diagnostic B-CLPD samples, and at the same
time it provides a valuable tool for the design of new
comprehensive multicolor antibody panels support, both for
diagnosis and minimal residual disease monitoring of B-CLPD
and other hematological malignancies.
Materials and methods
Patients and samples
EDTA-anticoagulated PB (n¼99), bone marrow (n¼105)
samples plus one pleural effusion were collected at diagnosis
from 205 patients suffering from small B-cell CLPDF118 males
and 87 females; median age of 66 years (range: 26–93 years).
According to the WHO criteria,
24 patients were grouped
as follows: B-cell chronic lymphocytic leukemias (B-CLL), 120
patients (100 typical and 20 atypical B-CLL cases); lympho-
plasmacytic lymphoma, 5 cases; mantle cell lymphoma (MCL),
34 cases; splenic marginal zone lymphoma, 5 cases; mucosa-
associated lymphoid tissue lymphoma, 7 cases, and follicular
lymphoma (FL), 34 patients.
Median PB lymphocyte counts at diagnosis were of
18.6 10
9 lymphocytes/l (range: 0.8–286 10
9 lymphocytes/l);
in turn, the mean percentage of neoplastic B-cells in the
samples analyzed was of 36.9±27.9% (range: 0.2–96.8%)
Fmedian of 58.2% (range 2.1–96.8%) vs 13.7% (range:
0.2–90.9%) in PB vs bone marrow samples, respectively.
All individuals gave their informed consent before entering the
study and the study was approved by the local Ethical
Committee of the University Hospital of Salamanca (Salamanca,
Spain).
Flow cytometry immunophenotyping
For the research purposes of the study, the following multi-
parameter ﬂow cytometry panel of 3- and 4-color combinations
of MAbFﬂuorescein isothyocyanate/ phycoerythrin/ peridinin
chlorophyll protein-cyanin 5.5 (PerCP Cy5.5)/ allophycocyanin
(APC)Ftested in every individual sample, was used: FMC7/
CD24/CD19/CD34, CD22/CD23/CD19/CD20, CD103/CD25/
CD19/CD11c, CD43/CD79b/CD19/-, surface immunoglobulin
(sIg)l/(sIg)k/CD19/CD5, sIgM/CD27/CD19/- and cytoplasmic
Cybcl2/CD10/CD19/CD38.
In every case, a stain, lyse and then wash, direct immuno-
ﬂuorescence technique was used following consensus recom-
mendations.
21,25 Brieﬂy, pre-titrated amounts of each MAb in
a combination were added to separate aliquots containing
0.12–1 10
6 white blood cells in 100ml of sample, depending
on the white blood cells count of each sample, for example,
appropriate dilution with phosphate-buffered saline (pH¼7.4)
was performed for samples with nucleated cell counts
410 10
9/l, and gentle mixed. After 15min of incubation, at
room temperature in the darkness, 2ml of FACS lysing solution
(Becton/Dickinson BiosciencesFBD, San Jose, CA, USA),
diluted 1/10 (v/v) in distilled water, was added; after gentle
mixing, another incubation was performed, (10min at room
temperature in the darkness). Samples were then washed in 4ml
phosphate-buffered saline/ aliquot (5min at 540g) and measured
in a FACSCalibur ﬂow cytometer (BD). For immunophenotypic
staining of surface immunoglobulins, the cells were washed
twice in 2ml phosphate-buffered saline with 0.5% albumin/
aliquot, before staining with the corresponding antibodies.
For immunophenotypic staining of Cybcl2, the Fix and Perm
reagent kit (Invitrogen, Carlsbad, CA, USA) was used, strictly
following the recommendations of the manufacturer.
Information about 5 10
4 leukocytes/aliquot was acquired
and stored, using the CellQUEST software (BD). For samples
with low B-cell percentages (o10%), additional information
about X5 10
4 CD19
þ/SSC
lo B-cells was acquired through an
electronic live gate set on a CD19 vs sideward light scatter (SSC)
dot plot, and stored using the CellQUEST software, as previously
described.
17
Merge of ﬂow cytometry data ﬁles and calculation
of ﬂow cytometric data
Merge of data ﬁles corresponding to different aliquots of each
individual sample and calculation of ﬂow cytometry data were
performed as previously described in detail,
14 after gating on
CD19
þ neoplastic B-cells. Brieﬂy, CD19
þ neoplastic B-cells
were selected for each data ﬁle with the INFINICYT software
(Cytognos SL, Salamanca, Spain), using conventional gating
strategies based on their unique patterns of antigen expression,
19
as illustrated in Supplementary Figure 1. Information restricted
to the selected neoplastic B-cells was stored in new separate
data ﬁles corresponding to each individual sample aliquot.
Then, data about neoplastic B-cells contained in each of these
new data ﬁles for each multicolor staining performed on
individual samples was merged into a single data ﬁle using the
INFINICYT software program. Afterward, information about
each individual parameter contained in this new merged
ﬁle, which was not actually measured for an individual event,
was calculated for the overall panel of markers analyzed; such
calculation was done for each event measured using the
calculation function of the INFINICYT software, based on
nearest-neighbour statistical tools.
26,27 For this purpose, those
three parameters which were measured in common in every
multicolor staining, forward light scatter (FSC) and SSC, as well
as CD19 PerCP Cy5.5, were used to search for each event’s
nearest-neighbour. All other immunophenotypic parameters
were only measured for the subset of cellular events corre-
sponding to the speciﬁc multicolor staining from the whole
multi-tube panel where they were speciﬁcally assessed;
calculation of the values for each of these latter parameters
(for individual cellular events) where they were not directly
assessed, was based on the assignment of those values observed
for their nearest-neighbour event contained in another aliquot
of the same sample, for which staining for those speciﬁc
parameters had been performed.
After merging the original 4-color (6-parameter) data ﬁles and
calculating the ‘missing’ values initially lacking for each
individual event, a single data ﬁle containing information about
all parameters measured in all multicolor stainings, for each of
the events recorded, was obtained. Therefore, each of the
merged/calculated data ﬁle ﬁnally contained information about
all parameters measured (n¼20); which were: FSC, SSC, CD19,
CD22, CD23, CD20, CD103, CD25, CD11c, FMC7, CD24,
CD34, CD43, CD79b, sIgM, CD27, CD5, Cybcl2, CD10 and
CD38, for each of the X2.0 10
5 events analyzed per sample
(four aliquots/sample each containing information about
X5 10
4 B-cell events). sIgk and sIgl measurements were
excluded from the calculated data ﬁles as light chain restriction
varies among sIgkþ and sIglþ cases, and thus its staining can
not be used as a single parameter for disease classiﬁcation.
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LeukemiaGeneration of reference data ﬁles for speciﬁc
small B-cell CLPD WHO entities
Three reference groups corresponding to three different small
B-cell CLPD entities (typical B-CLL, MCL and FL) were
generated with a subgroup of 30 B-CLPD cases. For these three
groups, 10 typical B-CLL, 10 MCL and 10 FL cases were
randomly selected from the 205 small B-cell CLPD cases
analyzed. Supplementary Table 1 shows detailed phenotypic
and genetic features of these 30 reference cases (reference data
set), as well as of the other 175 patients (testing set) analyzed.
Afterward, PCA was applied and graphically visualized
through the automated population separator (APS) view of the
INFINICYT software (Figures 1a–c). In this APS view, the ﬁrst
(x axis) and second (y axis) principal components are used to
produce a bidimensional representation of phenotypic proﬁles.
Each principal component is a linear combination of parameters
with distinct weights, allowing for a bidimensional representa-
tion with most of the information of the original higher
dimension space being preserved. We opted for PCA for two
reasons: (1) it reduces dimensionality of feature space by
restricting attention to those directions along which the scatter
is greater; (2) linear combinations are easy to compute. The ﬁrst
and second principal components were used since others (third,
fourth and so on) did not provide signiﬁcantly relevant
additional information for the discrimination among cases with
different diagnosis.
In the next step, each case was tested (PCA) against the three
‘reference-groups’ in a one vs one comparison: B-CLL vs MCL,
B-CLL vs FL and MCL vs FL, (Figures 1d–f, respectively), for a
total of 525 comparisons (175 cases tested for three compar-
isons/case). The set of 30 reference cases were excluded in this
testing out of sample phase. For each comparison, individual
data ﬁles corresponding to neoplastic B-cells from each sample
were merged with each of the three previously constructed pairs
of reference data ﬁles. For classiﬁcation purposes, the ﬁrst vs
second principal components of the PCA transformation,
15,28
were considered (APS representation shown in Figure 1).
Afterward, mean PCA 1 and PCA 2 values were calculated for
the neoplastic B-cell events corresponding to each tested
case and the reference cases and represented in the PCA space
(APS view of the ﬁrst vs second principal components) as a
single square dot (Figures 1g–i). The tested case was then
assigned to its nearest reference entity in the APS space, except
if it fell outside the three reference groups, to which it was
compared; in this latter situation, patients were classiﬁed as
different from all three reference groups (for example, other
B-CLPD). Finally, we compared the results of PCA-analysis of
only immunophenotypes against the full WHO clinical diag-
nosis established on the basis of the patients‘ clinical features,
histopathology and cytogenetics besides conventional immuno-
phenotyping. Subsequently, we calculated the sensitivity,
speciﬁcity, positive predictive (PPV) and negative predictive
(NPV) values of the new (PCA-guided) approach for the
diagnosis of B-cell CLPD, using the WHO classiﬁcation as a
gold standard.
Other statistical methods
All numerical and coded data derived from ﬂow cytometric studies
were introduced in a database using the SPSS program (SPSS 15.0,
Chicago, IL, USA). For each continuous variable analyzed, mean
values and their standard deviation (s.d.), as well as the median
and the 95% conﬁdence interval, were calculated. In order to
assess the statistical signiﬁcance of differences observed between
groups, the Mann–Whitney U-test was used. P-values o0.05 were
considered to be associated with statistical signiﬁcance.
ab c
f e d
MCL reference group
MCL case – 111
CLL case – 42
CLL reference group
FL reference group
i h g
FL case – 19
S
e
c
o
n
d
 
p
r
i
n
c
i
p
a
l
 
c
o
m
p
o
n
e
n
t
LPL case – 102
First principal component
APS 1 APS 1 APS 1
APS 1 APS 1 APS 1
APS 1 APS 1 APS 1
Figure 1 Illustrating example of the CLL vs MCL (a, d and g), CLL vs FL (b, e and h) and FL vs MCL (c, f and i) one vs one comparisons of ﬂow
cytometry data ﬁles corresponding to the three B-CLPD reference groups as classiﬁed by the PCA projections (ﬁrst vs second principal
components). The PCA based classiﬁcation proﬁle obtained for four cases tested is displayed: a typical CLL (brown dots), one FL (dark green dots),
a MCL (dark blue dots) and a lymphoplasmacytic lymphoma (LPL; black dots). In a–f, each dot corresponds to a single cell event, whereas in panels
g–h, mean principal component 1 vs principal component 2 values for each case (same PCA as in panels d–f, respectively), are shown.
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As described above, three reference groups of 10 cases each
were established and compared in a one vs one basis; these
three reference groups contained ‘reference’ typical B-CLL, FL
and MCL cases colored in red, green and blue in Figure 1,
respectively. Then, each of the one vs one comparison was
represented in a PCA space deﬁned by the ﬁrst vs the second
principal components (Figures 1a–c). Each case from the test
group was compared in the same three PCA spaces against the
pairs of B-CLL vs MCL, B-CLL vs FL and MCL vs FL reference
groups, as illustrated for four different cases in Figures 1g–i.
Based on these comparisons, each case was classiﬁed as typical
CLL, MCL, FL or other B-CLPD. For each comparison, we
recorded the sequence of parameters which had the greater
weight in the discrimination between each pair of diagnostic
B-CLPD entities and their relative contribution to such discri-
mination value for each comparison (Supplementary Table 2).
The most informative markers were: (1) CD23, CD5, CD27,
CD10, CD43, CD20 and CD38 for the discrimination between
B-CLL vs FL; (2) CD23, CD38, CD20, sIgM, CD79b and FMC7
for B-CLL vs MCL and (3) CD5, sIgM, CD27, CD10, CD25 and
CD19 for the distinction between MCL vs FL (Supplementary
Table 2).
Overall, the efﬁciency of the approach here evaluated for
correct assignment of the 175 B-CLPD cases analyzed to
the three pre-established reference groups was of 89%
(n¼155/175) with a speciﬁcity of 89% and a sensitivity of
96%; the positive and negative predictive values were of 89 and
96%, respectively (Table 1).
In detail, 88/89 (99%) typical B-CLL cases and 11/20 (55%)
atypical B-CLL patients were correctly assigned to the B-CLL
group. From the other 9 atypical B-CLL patients, 8 were
classiﬁed as not clearly belonging to any of the three reference
groups, and the other case was misclassiﬁed as MCL (Table 2
and Supplementary Table 3). Interestingly, 5/8 misclassiﬁed
cases of atypical B-CLL had multiple atypical phenotypic
characteristics (for example, CD20
hi, FMC7
hi and CD79b
hi).
Furthermore, these atypical B-CLL cases had trisomy 12, either
as the sole genetic abnormality (n¼3) or in association with
del(13q) (n¼1) or del(17q) (n¼1), 1/8 showed del(17q) and 1/8
had del(13q) (Supplementary Table 1); in turn, the misclassiﬁed
case (case ID: 29), showed del(11q) in the absence of t(11;14)
(Supplementary Table 1). Based on these results, the sensitivity
and speciﬁcity reached for typical B-CLL were of 99 and 100%,
respectively, and for all B-CLL casesFtypical plus atypicalFof
91 and 100%, respectively (PPV of 100% and NPV of 88%)
(Table 1).
Regarding MCL cases, 23/24 (96.8%) patients were correctly
assigned to the MCL (Table 2 and Supplementary Table 3); the
other MCL patient was misclassiﬁed as FL; of note this case (case
ID: 120) showed t(11;14) in association with del(17p), besides
an atypical CD5
  immunophenotype, in the absence of t(14;18)
(Table 2 and Supplementary Table 3). Based on these results, a
sensitivity of 97% and a speciﬁcity of 96% were obtained for the
MCL group, with a NPV of 99% and a PPV of 77% (Table 1).
Similarly, most (22/24 cases; 91.7%) FL cases were also
correctly assigned to the FL group (Table 2 and Supplementary
Table 3). Of note, the two misclassiﬁed cases were assigned to
the MCL group; interestingly, these two patients could not be
diagnosed on histopathological grounds alone, but they both
showed the presence of t(14;18) in association with trisomy 12,
and no t(11;14); one of these cases had a CD5
þ phenotype
(Supplementary Table 1). Based on these results, the overall
sensitivity and speciﬁcity for correct assignment of FL cases were
of 92 and 98%, respectively (PPV of 85% and NPV of 99%)
(Table 1).
In all, 10 out of the other 17 (58.8%) small B-cell CLPD
studied (5 lymphoplasmacytic lymphoma, 7 mucosa-associated
Table 1 Sensitivity, speciﬁcity and both positive and negative
predictive values of the PCA-based classiﬁcation approach for B-CLPD
according to the expression of CD22, CD23, CD20, CD103, CD25,
CD11c, CD43, CD79b, FMC7, CD24, CD34, CD5, sIgM, CD27,
Cybcl2, CD10 and CD38 on neoplastic B-cells
Diagnostic Subgroups Sensitivity Speciﬁcity Positive
predictive
value
Negative
predictive
value
Total B-CLL 91% 100% 100% 88%
Typical B-CLL 99% 100% 100% 99%
Atypical B-CLL 55% 100% 100% 89%
MCL 97% 96% 77% 99%
FL 92% 98% 85% 99%
Other 59% 94% 53% 96%
Total 89% 96% 89% 96%
Abbreviations: B-CLPD, B-cell chronic lymphoproliferative diseases;
B-CLL, B-cell chronic lymphocytic leukemia; MCL, mantle cell
lymphoma; FL, follicular lymphoma; PCA, principal component
analysis.
Table 2 Frequency of B-CLPD cases classiﬁed according to the WHO, assigned to the different reference subgroups using the proposed
phenotype-based PCA classiﬁcation approach
WHO diagnostic subgroups Immunophenotypic subgroups deﬁned by the automated PCA classiﬁcation approach
B-CLL MCL FL Other
Typical B-CLL 89/90 (99%) 0 (0%) 0 (0%) 1/90 (1%)
a
Atypical B-CLL 11/20 (55%) 1/20 (5%)
b 0 (0%) 8/20 (40%)
MCL 0 (0%) 23/24 (96.8%) 1/24 (4.2%)
c 0 (0%)
FL 0 (0%) 2/24 (9.5%)
d 22/24 (91.7%) 0 (0%)
Other 0 (0%) 4/17 (23.5%) 3/17 (17.7%) 10/17 (58.8%)
Abbreviations: B-CLPD, B-cell chronic lymphoproliferative disorders; B-CLL, chronic lymphocytic leukemia; MCL; mantle cell lymphoma;
FL, follicular lymphoma; PCA, principal component analysis; WHO, World Health Organization.
aOne B-CLL case with a CD23
  phenotype and both del(11q) and del(13q).
bAtypical B-CLL case with a CD20
+++ and FMC7
++ phenotype.
cCase corresponding to a t(11;14)
+ MCL with a CD5
  phenotype and additional del(17p).
dBoth cases corresponded to a FL with t(14;18)
+, which were unclassiﬁable as such on histopathological grounds alone; one of them had
a CD5
+ phenotype in association with trisomy 12.
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Leukemialymphoid tissue lymphomas and 5 splenic marginal zone
lymphoma) were correctly identiﬁed as different from B-CLL,
FL and MCL. Four of the other seven cases were assigned to
the MCL group and three to the FL group (Table 2 and
Supplementary Table 3); none of them was misclassiﬁed as
belonging to the B-CLL group. Thus, the overall sensitivity and
speciﬁcity for this latter group was of 59 and 94%, respectively
(NPV of 53% and PPV 96%).
Discussion
Currently, the utility of immunophenotyping is highly variable
and heterogeneous depending on the speciﬁc IP of the
individual cases investigated.
8,9,11–13,29 As an example, among
B-CLPD it is recognized that immunophenotyping is extremely
powerful in the differential diagnosis between typical B-CLL,
hairy cell leukemia and other disease entities; its reliability
progressively decreases from MCL and FL to MZL.
30–32 Several
factors contribute to such variability, which include: (i) the lack
of robust individual markers to efﬁciently deﬁne each disease
entity, leading to the need for interpretation of complex IPs; (ii)
the biological variability of individual disease entities, with
overlapping features between different WHO diagnostic sub-
groups and (iii) the lack of standardized criteria and procedures
for interpretation of complex ﬂow cytometry proﬁles.
9,16–19,22
Initially, efforts have mainly concentrated on the identiﬁca-
tion of new, highly informative markers;
7,18,30–33 this has led
to the use of progressively large panels of reagents. Latter on,
standardization efforts have focused on providing recommenda-
tions and guidelines as regards: (i) the speciﬁc techniques
applied for sample preparation and staining, (ii) the most
informative, mandatory markers and (iii) scoring systems for
standardized clear-cut deﬁnition of individual disease enti-
ties.
7,20,21 Altogether, these efforts have improved the reprodu-
cibility of immunophenotyping, but at the expense of increasing
the complexity of interpretation of the ﬂow cytometric data,
which typically requires highly-qualiﬁed and experienced
professionals.
7
In a certain way, in the last decades an objective technique
such as multiparameter ﬂow cytometry immunophenotyping,
has progressively evolved into a process based on a relative
subjective expert-based interpretation of histograms and bivari-
ate dot plots (for example, ‘FCM images’) similar to that of
conventional pathology (‘morphological and histopathological
microscopic images’).
34 More recently, attempts have been
made to apply expert supervised algorithms and approaches (for
example, Bayesian algorithms) to a more accurate classiﬁcation
of B-CLPD and other hematological neoplasias.
10,35 However,
in these studies, values for individual markers are either
expressed as mean/median values (for example, mean ﬂuores-
cence intensity) for a cell population or they are translated into
an arbitrary categorical classiﬁcation of negative vs positive and
dim vs bright patterns of marker expression, before the use of the
derived algorithm; this a priori manipulation of data, may
introduce a bias with a negative impact on the performance of
the algorithm used.
In this study, we applied and evaluated a mathematical
procedure, which has been recently proposed, for the classiﬁca-
tion of individual patients into pre-established and well-deﬁned
WHO diagnostic entities. A detailed description of the
mathematical algorithm has been previously reported by our
group
15 and they have become widely available as friendly
tools incorporated into commercial ﬂow cytometry data
analysis software. For this propose, we selected a model of
heterogeneous overlapping diseasesFsmall B-CLPDFto per-
form a retrospective study of a series of 205 PB and bone
marrow patient samples (30 samples were used to build the
model and the other 175 to test it). The new mathematical tools
used allow calculation of the complete immunophenotypic
information derived from distinct aliquots of the same sample,
for every individual cell measured in all sample aliquots;
14 In
addition, they permit generation of reference data ﬁles contain-
ing information about neoplastic B-cells from several patients
which are selected as representative of individual, well-deﬁned
WHO entities (for example, B-CLL, MCL and FL); afterward,
unsupervised pattern recognition multivariate analysisFfor
example PCAF
15,28 can be easily applied to compare each
case interrogated against (for example, two) reference disease
groups. In fact, in our study, to reduce the dimensionality of the
data, we just considered the ﬁrst vs second principal compo-
nents. Noteworthy, this procedure showed an overall efﬁciency
of 485%, for the classiﬁcation of a relatively large group of
small B-cell CLPD into speciﬁc WHO disease groups. To the
best of our knowledge, this is the ﬁrst time that such a
procedure, based on information derived from phenotypic
proﬁling of individual tumor cells, is proposed to guide/help
the expert on the interpretation of their overall immunopheno-
typic pattern, in the diagnostic work-up of hematological
malignancies. The level of efﬁciency reached was particularly
high among typical CLL, MCL and FL with only a few (n¼4)
discrepant cases: one corresponded to an atypical CD5
  MCL,
another to a CD5
þ FL and a third case to a FL which could also
not be classiﬁed as such, based on strict histopathological or
immunophenotypic criteria alone.
Despite this, 11% of false or undetermined diagnoses were
found which is higher than desirable. Noteworthy, most of the
cases were found among those disease entities for which reference
IP groups were not used in our study (for example: splenic
marginal zone lymphoma, lymphoplasmacytic lymphoma and
mucosa-associated lymphoid tissue lymphomas, as well as in
atypical B-CLL). Although this could be viewed as a failure of
the newly proposed procedure, it more likely reﬂects the need
for additional markers to be included in this MAb panel. In fact,
it is generally known that with the restricted panel of reagents
used, entities such as splenic marginal zone lymphoma and
lymphoplasmacytic lymphoma can not be clearly deﬁned on
immunophenotypic grounds, requiring additional markers and
information.
25,36,37 Alternatively, some WHO diagnostic groups
might actually correspond to a heterogeneous group of different
disorders. In line with this latter hypothesis, it should be noted
that a major fraction of all atypical B-CLL cases was actually
properly classiﬁed as such, whereas another subgroup of
patients was considered to be clearly different, not only from
B-CLL, but also from MCL and FL. Further investigations on
larger series of patients in which reference groups for atypical
B-CLL and other small B-cell CLPD are also included, are
required to deﬁne the precise value of this new tool in these and
other subtypes of B-CLPD, as well as in acute leukemias and
other hematological malignancies.
Overall, these results show that when combined with the
mathematical approach used, currently available 3- and 4-color
panels work relatively well, but they are suboptimal for the
classiﬁcation of some B-CLPD disease entities. Accordingly,
with this new strategy the performance of a panel of reagents
can be objectively monitored and evaluated in terms of its rate
of failure, pointing to the need for improved panels. However,
it should be noted that for each new panel designed, a new set
of reference data ﬁles, which had been stained with it and
measured under comparable conditions, is required.
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LeukemiaIn summary, here we describe a new powerful tool that can
be used in the future to help expert-based interpretation of
multiparameter ﬂow cytometry immunophenotypic data in the
subclassiﬁcation of hematological malignances. The proposed
strategy may also contribute to a better deﬁnition of speciﬁc
subgroups of diseases and to improve standardization of
interpretation of ﬂow cytometry data, and it can be applied for
the evaluation of the performance of currently used antibody
panels for immunophenotypic classiﬁcation of B-CLPD and
other malignancies.
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